MX2016007809A - Espiro-oxazolonas. - Google Patents
Espiro-oxazolonas.Info
- Publication number
- MX2016007809A MX2016007809A MX2016007809A MX2016007809A MX2016007809A MX 2016007809 A MX2016007809 A MX 2016007809A MX 2016007809 A MX2016007809 A MX 2016007809A MX 2016007809 A MX2016007809 A MX 2016007809A MX 2016007809 A MX2016007809 A MX 2016007809A
- Authority
- MX
- Mexico
- Prior art keywords
- oxazolones
- disorders
- spiro
- present
- vasopressin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona espiro-oxazolonas, que actúan como moduladores del receptor V1a, y en particular, como antagonistas del receptor V1a, a su fabricación, a composiciones farmacéuticas que los contienen y a su uso como medicamentos. Los presentes compuestos son útiles como agentes terapéuticos que actúan de manera periférica y central en condiciones de secreción inadecuada de vasopresina, ansiedad, trastornos depresivos, trastorno obsesivo-compulsivo, trastornos del espectro autista, esquizofrenia, comportamiento agresivo y trastornos del sueño por cambio de fase, en particular, descompensación horaria.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198604 | 2013-12-19 | ||
| PCT/EP2014/077858 WO2015091411A1 (en) | 2013-12-19 | 2014-12-16 | Spiro-oxazolones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016007809A true MX2016007809A (es) | 2016-09-07 |
| MX370663B MX370663B (es) | 2019-12-19 |
Family
ID=49876427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007809A MX370663B (es) | 2013-12-19 | 2014-12-16 | Espiro-oxazolonas. |
Country Status (35)
| Country | Link |
|---|---|
| US (3) | US10479796B2 (es) |
| EP (1) | EP3083633B1 (es) |
| JP (1) | JP6530407B2 (es) |
| KR (1) | KR102353431B1 (es) |
| CN (1) | CN105814062B (es) |
| AR (1) | AR098783A1 (es) |
| AU (1) | AU2014364729B2 (es) |
| BR (1) | BR112016013058B1 (es) |
| CA (1) | CA2932063C (es) |
| CL (1) | CL2016001495A1 (es) |
| CR (1) | CR20160215A (es) |
| DK (1) | DK3083633T3 (es) |
| EA (1) | EA029167B1 (es) |
| ES (1) | ES2657994T3 (es) |
| HK (1) | HK1223920A1 (es) |
| HR (1) | HRP20180160T1 (es) |
| HU (1) | HUE036203T2 (es) |
| IL (1) | IL245464B (es) |
| LT (1) | LT3083633T (es) |
| MA (1) | MA39139B1 (es) |
| MX (1) | MX370663B (es) |
| MY (1) | MY177313A (es) |
| NO (1) | NO3083633T3 (es) |
| NZ (1) | NZ719765A (es) |
| PE (1) | PE20160864A1 (es) |
| PH (1) | PH12016500919B1 (es) |
| PL (1) | PL3083633T3 (es) |
| PT (1) | PT3083633T (es) |
| RS (1) | RS56791B1 (es) |
| SG (1) | SG11201604915PA (es) |
| SI (1) | SI3083633T1 (es) |
| TW (1) | TWI548639B (es) |
| UA (1) | UA117273C2 (es) |
| WO (1) | WO2015091411A1 (es) |
| ZA (1) | ZA201603221B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201600522A (zh) * | 2014-02-20 | 2016-01-01 | 赫孚孟拉羅股份公司 | 螺－唑酮 |
| WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
| AR127706A1 (es) | 2021-11-19 | 2024-02-21 | Hoffmann La Roche | Síntesis de 2-(7,7-dimetil-1h,7h-espiro[furo[3,4-b]piridin-5,4-piperidin]-1-il)-1,3-dihidro-4h-espiro[inden-2,5-[1,3]oxazol]-4-ona |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7365079B2 (en) * | 2002-11-29 | 2008-04-29 | Banyu Pharmaceutical Co., Ltd. | Azole derivatives |
| US7351706B2 (en) | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| MX2009005507A (es) * | 2006-12-07 | 2009-06-03 | Hoffmann La Roche | Derivados de espiro-piperidina. |
| RU2009123134A (ru) * | 2006-12-22 | 2011-01-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные спиро-пиперидина |
| ATE536356T1 (de) * | 2007-01-12 | 2011-12-15 | Hoffmann La Roche | Spiropiperidin-glycinamid-derivate |
| KR101348499B1 (ko) * | 2008-11-13 | 2014-01-06 | 에프. 호프만-라 로슈 아게 | 스피로-5,6-다이하이드로-4ｈ-2,3,5,10ｂ-테트라아자-벤조〔ｅ〕아줄렌 |
-
2014
- 2014-12-16 PL PL14815318T patent/PL3083633T3/pl unknown
- 2014-12-16 MX MX2016007809A patent/MX370663B/es active IP Right Grant
- 2014-12-16 HU HUE14815318A patent/HUE036203T2/hu unknown
- 2014-12-16 NO NO14815318A patent/NO3083633T3/no unknown
- 2014-12-16 JP JP2016541359A patent/JP6530407B2/ja active Active
- 2014-12-16 CN CN201480067988.1A patent/CN105814062B/zh active Active
- 2014-12-16 EP EP14815318.2A patent/EP3083633B1/en active Active
- 2014-12-16 RS RS20180097A patent/RS56791B1/sr unknown
- 2014-12-16 KR KR1020167019366A patent/KR102353431B1/ko active IP Right Grant
- 2014-12-16 SG SG11201604915PA patent/SG11201604915PA/en unknown
- 2014-12-16 ES ES14815318.2T patent/ES2657994T3/es active Active
- 2014-12-16 NZ NZ719765A patent/NZ719765A/en unknown
- 2014-12-16 WO PCT/EP2014/077858 patent/WO2015091411A1/en active Application Filing
- 2014-12-16 LT LTEP14815318.2T patent/LT3083633T/lt unknown
- 2014-12-16 AU AU2014364729A patent/AU2014364729B2/en active Active
- 2014-12-16 SI SI201430574T patent/SI3083633T1/en unknown
- 2014-12-16 PE PE2016000722A patent/PE20160864A1/es unknown
- 2014-12-16 MY MYPI2016001019A patent/MY177313A/en unknown
- 2014-12-16 UA UAA201607813A patent/UA117273C2/uk unknown
- 2014-12-16 DK DK14815318.2T patent/DK3083633T3/da active
- 2014-12-16 CA CA2932063A patent/CA2932063C/en active Active
- 2014-12-16 MA MA39139A patent/MA39139B1/fr unknown
- 2014-12-16 EA EA201691189A patent/EA029167B1/ru not_active IP Right Cessation
- 2014-12-16 BR BR112016013058-8A patent/BR112016013058B1/pt active IP Right Grant
- 2014-12-16 PT PT148153182T patent/PT3083633T/pt unknown
- 2014-12-17 AR ARP140104703A patent/AR098783A1/es active IP Right Grant
- 2014-12-18 TW TW103144383A patent/TWI548639B/zh active
-
2016
- 2016-05-03 IL IL24546416A patent/IL245464B/en active IP Right Grant
- 2016-05-05 CR CR20160215A patent/CR20160215A/es unknown
- 2016-05-12 ZA ZA2016/03221A patent/ZA201603221B/en unknown
- 2016-05-18 PH PH12016500919A patent/PH12016500919B1/en unknown
- 2016-06-06 US US15/174,674 patent/US10479796B2/en active Active
- 2016-06-15 CL CL2016001495A patent/CL2016001495A1/es unknown
- 2016-10-19 HK HK16112054.0A patent/HK1223920A1/zh unknown
-
2018
- 2018-01-29 HR HRP20180160TT patent/HRP20180160T1/hr unknown
-
2019
- 2019-10-08 US US16/596,293 patent/US11578077B2/en active Active
-
2022
- 2022-11-29 US US18/059,554 patent/US20230106150A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501192A1 (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| CL2014002334A1 (es) | Compuestos derivados de indanos espirofusionados, inhibidores de la beta-secretasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como deterioro cognitivo, trastornos neurodegenerativos, demencia, entre otras. | |
| MX2013011054A (es) | Antagonistas de trpvi. | |
| HK1206615A1 (en) | Mglu2/3 antagonists for the treatment of autistic disorders mglu2/3 | |
| NZ730334A (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| ZA201506537B (en) | Prolonged delivery of certain fragrance components from personal care compositions | |
| UA116889C2 (uk) | Фармацевтична композиція, що містить суміш ізоформ apg101 (cd95-fc) | |
| PH12015501302A1 (en) | Compositions comprising vortioxetine and donepezil | |
| TN2014000136A1 (en) | Selective androgen receptor modulators | |
| PH12016500124A1 (en) | Via antagonists to treat phase shift sleep disorders | |
| IN2014KN02993A (es) | ||
| MX2014003600A (es) | Ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenos como antagonistas v1a. | |
| PH12016500919A1 (en) | Spiro-oxazolones | |
| MX2016009501A (es) | Espiro-oxazolonas. | |
| NZ702239A (en) | Heteroaryl compounds and methods of use thereof | |
| ITRM20120405A1 (it) | Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac | |
| PH12017500891A1 (en) | Spiro-thiazolones | |
| EA201591770A1 (ru) | Таксоиды - принцип очистки для жидких наполнителей | |
| IN2015DN02646A (es) | ||
| MX2014003643A (es) | Oxi-ciclohexil-4h,6h-5-oxa-2,3,10b-triaza-benzo[e] azulenos como antagonistas de v1a. | |
| UA76841U (en) | Feed additive "echinobioactive" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |